Catastrophic Antiphospholipid Syndrome Global Market Report 2025
상품코드:1810848
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
파국성 항인지질증후군 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 2029년 연평균 성장률(CAGR)은 10.4%로 61억 7,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장의 배경에는 자가면역질환의 유병률 증가, 의료 전문가들의 인식 개선, 면역억제요법 사용 확대, 혈전증 관련 합병증 발생률 증가, 고급 진단 도구에 대한 수요 증가 등이 있습니다. 이 기간의 주요 동향으로는 자가 항체 검출 기술의 발전, 현장 진단 기기의 개발, 임상 판단 지원 시스템에 인공지능의 통합, 면역측정 플랫폼의 기술 발전, 표적 생물학적 제제 및 단클론항체 개발 등이 있습니다.
자가 면역 질환의 유병률 증가는 향후 몇 년 동안 파국성 항인지질증후군 시장의 성장을 촉진할 것으로 예상됩니다. 자가면역질환은 면역체계가 과도하게 활성화되어 체내의 건강한 세포와 조직을 공격함으로써 발생합니다. 이러한 증가는 면역기능을 교란시키고 비정상적인 면역반응을 유발하는 환경오염물질에 대한 노출 증가에 기인합니다. 자가면역질환은 항인지질 항체의 생성을 촉진하고 광범위한 혈액 응고와 다장기 부전을 유발하여 파국성 항인지질증후군의 원인이 되고 있습니다. 예를 들어, 2023년 6월 비영리단체인 캐나다 크론병 및 대장염 재단은 캐나다에서 32만 2,600명이 염증성 장질환을 앓고 있으며, 이 수치는 2035년까지 47만 명으로 증가하고, 연간 신규 환자 수는 1만 1,000명에서 1만 4,000명으로 증가할 것으로 전망하고 있습니다. 따라서 자가 면역 질환의 유병률 증가는 파국성 항인지질증후군 시장을 주도하고 있습니다.
헬스케어 지출 증가는 파국성 항인지질증후군 시장의 향후 성장을 지원할 것으로 예상됩니다. 헬스케어 지출에는 개인, 정부, 조직이 헬스케어 서비스, 상품, 공중보건에 투자하는 총 재정적 자원이 포함됩니다. 일반적으로 노인은 더 빈번하고 집중적인 의료 서비스를 필요로 하기 때문에 고령화로 인해 이러한 지출이 증가하고 있습니다. 의료비 지출 증가는 고급 진단, 집중 치료, 항응고제, 면역 억제제, 혈장 분리술과 같은 중요한 치료에 대한 접근성을 제공함으로써 파국성 항인지질증후군 환자들에게 혜택을 줄 수 있습니다. 예를 들어, 2023년 5월 영국 통계청이 발표한 잠정 추산에 따르면 2022년 의료비 지출은 약 3,317억 달러(2,830억 파운드)로 2021년 대비 명목상 0.7% 증가할 것으로 예상됩니다. 따라서, 의료 지출의 증가는 파국성 항인지질증후군 시장의 성장을 촉진하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 파국성 항인지질증후군 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 파국성 항인지질증후군 시장 : 성장률 분석
세계의 파국성 항인지질증후군 시장 실적 : 규모와 성장, 2019-2024
세계의 파국성 항인지질증후군 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 파국성 항인지질증후군 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 파국성 항인지질증후군 시장 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
항응고제
면역 억제 요법
혈장 교환 요법(혈장 교환 요법)
정맥내 면역글로불린(IVIG)
기타 치료법
세계의 파국성 항인지질증후군 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구
비경구
세계의 파국성 항인지질증후군 시장 진단 툴별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
혈액 검사
영상 기술
유전자 검사
세계의 파국성 항인지질증후군 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
전문 클리닉
외래 수술 센터
기타 최종사용자
세계의 파국성 항인지질증후군 시장 : 하위 세분화 항응고제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
헤파린
저분자량 헤파린(LMWH)
와파린
직접 경구용 항응고제(DOACs)
폰다파리눅스
세계의 파국성 항인지질증후군 시장 : 하위 세분화 면역 억제 요법(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
코르티코스테로이드
사이클로포스파미드
아자티오프린
마이코페놀레이트 모페틸
메토트렉세이트
세계의 파국성 항인지질증후군 시장 : 하위 세분화 혈장 교환 요법(혈장 교환 요법), 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
치료적 혈장 교환(Tpe)
이중 여과 혈장 교환(Dfpp)
원심 혈장 교환
막형혈장 교환 요법
세계의 파국성 항인지질증후군 시장 : 하위 세분화 정맥내 면역글로불린(IVIG), 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
표준 정맥내 면역글로불린(Ivig)
고용량 정맥내 면역글로불린(IVIG)
액체 정맥내 면역글로불린(Ivig)
동결건조 정맥내 면역글로불린(Ivig)
세계의 파국성 항인지질증후군 시장 : 하위 세분화 기타 치료법(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
단클론항체
보체 억제제
항혈소판제
항 종양괴사인자(TNF)제
장기 서포트 요법
제7장 지역별·국가별 분석
세계의 파국성 항인지질증후군 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 파국성 항인지질증후군 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
파국성 항인지질증후군 시장 : 경쟁 구도
파국성 항인지질증후군 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Bristol-Myers Squibb Company
AstraZeneca PLC.
Abbott Laboratories
Novartis AG.
Fresenius Kabi AG.
Eli Lilly and Company
Boehringer Ingelheim International GmbH
Apotex Inc.
Dr. Reddy's Laboratories Ltd.
Hikma Pharmaceuticals PLC
Aspen Pharmacare Holdings Limited
Zydus Lifesciences Limited
LEO Pharma A/S
Kedrion Biopharma Inc.
Amphastar Pharmaceuticals Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
파국성 항인지질증후군 시장 2029 : 새로운 기회를 제공하는 국가
파국성 항인지질증후군 시장 2029 : 새로운 기회를 제공하는 부문
파국성 항인지질증후군 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
KSM
영문 목차
영문목차
Catastrophic antiphospholipid syndrome (CAPS) is a rare and severe autoimmune condition characterized by rapid, widespread clotting in small blood vessels, resulting in multi-organ failure. It is caused by antiphospholipid antibodies and typically requires urgent treatment involving anticoagulants, steroids, and immunosuppressive medications.
The primary treatments for catastrophic antiphospholipid syndrome include anticoagulants, immunosuppressive therapies, plasma exchange (plasmapheresis), intravenous immunoglobulin (IVIG), and other options. Anticoagulants work by preventing or reducing blood clot formation through interference with the clotting process. These therapies can be administered orally or parenterally. Diagnosis often involves blood tests, imaging methods, and genetic testing. Treatment is provided by various healthcare settings, including hospitals, specialty clinics, ambulatory surgical centers, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The catastrophic antiphospholipid syndrome market research report is one of a series of new reports from The Business Research Company that provides catastrophic antiphospholipid syndrome market statistics, including the catastrophic antiphospholipid syndrome industry's global market size, regional shares, competitors with the catastrophic antiphospholipid syndrome market share, detailed catastrophic antiphospholipid syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the catastrophic antiphospholipid syndrome market. This catastrophic antiphospholipid syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The catastrophic antiphospholipid syndrome market size has grown rapidly in recent years. It will grow from $3.76 billion in 2024 to $4.16 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth during the historic period can be attributed to the increasing use of plasmapheresis and intravenous immunoglobulin (IVIG), expanded availability of biologics and monoclonal antibodies, enhanced patient support programs and rare disease advocacy, a rise in clinical trials for targeted therapies, and higher healthcare expenditures.
The catastrophic antiphospholipid syndrome market size is expected to see rapid growth in the next few years. It will grow to $6.17 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The expected growth in the forecast period can be attributed to the rising prevalence of autoimmune disorders, increased awareness among healthcare professionals, expanded use of immunosuppressive therapies, a growing incidence of thrombosis-related complications, and heightened demand for advanced diagnostic tools. Key trends during this period include improvements in autoantibody detection technologies, the creation of point-of-care diagnostic devices, integration of artificial intelligence in clinical decision support systems, technological advancements in immunoassay platforms, and the development of targeted biologics and monoclonal antibodies.
The rising prevalence of autoimmune disorders is expected to drive the growth of the catastrophic antiphospholipid syndrome market in the coming years. Autoimmune disorders occur when the immune system becomes overactive and attacks the body's own healthy cells and tissues. This increase is partly linked to greater exposure to environmental pollutants, which disrupt immune function and trigger abnormal immune responses. Autoimmune disorders contribute to catastrophic antiphospholipid syndrome by promoting the production of antiphospholipid antibodies, leading to widespread blood clotting and multi-organ failure. For example, in June 2023, the Crohn's and Colitis Foundation of Canada, a non-profit organization, reported that 322,600 people were living with inflammatory bowel disease in Canada, a figure expected to rise to 470,000 by 2035, with annual new cases increasing from 11,000 to 14,000. Therefore, the growing prevalence of autoimmune disorders is boosting the catastrophic antiphospholipid syndrome market.
The increasing healthcare expenditure is anticipated to support the growth of the catastrophic antiphospholipid syndrome market moving forward. Healthcare expenditure includes the total financial resources spent on health services, goods, and public health efforts by individuals, governments, and organizations. This spending is rising due to an aging population, as older adults generally require more frequent and intensive medical care. Higher healthcare expenditure benefits patients with catastrophic antiphospholipid syndrome by providing access to advanced diagnostics, intensive care, and critical treatments such as anticoagulation therapy, immunosuppressants, and plasmapheresis. For instance, provisional estimates from the UK's Office for National Statistics in May 2023 showed that healthcare expenditure reached approximately $331.70 billion (£283 billion) in 2022, marking a nominal increase of 0.7% compared to 2021. Hence, rising healthcare spending is fueling growth in the catastrophic antiphospholipid syndrome market.
The growth of the catastrophic antiphospholipid syndrome market is also being driven by an increase in clinical trials. Clinical trials are research studies conducted on human subjects to assess the safety, effectiveness, and side effects of medical treatments or interventions. The number of clinical trials is growing due to heightened demand for personalized and innovative therapies that require thorough safety and efficacy testing. Clinical trials contribute to better understanding, diagnosis, and treatment of catastrophic antiphospholipid syndrome by evaluating new therapies, improving existing treatments, and supporting evidence-based clinical practices. For example, in November 2023, the Association of the British Pharmaceutical Industry, a trade association based in London, reported a 15% increase in annual recruitment to industry clinical trials in the UK, rising from 36,722 participants in 2021-22 to 42,088 in 2022-23. Therefore, the rise in clinical trials is propelling the catastrophic antiphospholipid syndrome market growth.
Major players in the catastrophic antiphospholipid syndrome market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC., Abbott Laboratories, Novartis AG., Fresenius Kabi AG., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Apotex Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Limited, LEO Pharma A/S, Kedrion Biopharma Inc., Amphastar Pharmaceuticals Inc.
North America was the largest region in the catastrophic antiphospholipid syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in catastrophic antiphospholipid syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the catastrophic antiphospholipid syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The catastrophic antiphospholipid syndrome market consists of revenues earned by entities by providing services such as acute medical management, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The catastrophic antiphospholipid syndrome market also includes sales of antiphospholipid antibody test kits, anticoagulants, and immunosuppressive drugs. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Catastrophic Antiphospholipid Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on catastrophic antiphospholipid syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for catastrophic antiphospholipid syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The catastrophic antiphospholipid syndrome market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment: Anticoagulants; Immunosuppressive Therapy; Plasma Exchange Therapy (Plasmapheresis); Intravenous Immunoglobulin (IVIG); Other Treatments
2) By Route Of Administration: Oral; Parenteral
3) By Diagnostic Tools: Blood Testing; Imaging Techniques; Genetic Testing
4) By End-User: Hospitals; Specialty clinics; Ambulatory surgical centers; Other End-Users
Subsegments:
1) By Anticoagulants: Heparin; Low Molecular Weight Heparin (LMWH); Warfarin; Direct Oral Anticoagulants (DOACs); Fondaparinux
2) By Immunosuppressive Therapy: Corticosteroids; Cyclophosphamide; Azathioprine; Mycophenolate Mofetil; Methotrexate
5) By Other Treatments: Monoclonal Antibodies; Complement Inhibitors; Antiplatelet Agents; Anti-Tumor Necrosis Factor (Tnf) Agents; Organ Support Therapies
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC.; Abbott Laboratories; Novartis AG.; Fresenius Kabi AG.; Eli Lilly and Company; Boehringer Ingelheim International GmbH; Apotex Inc.; Dr. Reddy's Laboratories Ltd.; Hikma Pharmaceuticals PLC; Aspen Pharmacare Holdings Limited; Zydus Lifesciences Limited; LEO Pharma A/S; Kedrion Biopharma Inc.; Amphastar Pharmaceuticals Inc.
3. Catastrophic Antiphospholipid Syndrome Market Trends And Strategies
4. Catastrophic Antiphospholipid Syndrome Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Catastrophic Antiphospholipid Syndrome Growth Analysis And Strategic Analysis Framework
5.1. Global Catastrophic Antiphospholipid Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Catastrophic Antiphospholipid Syndrome Market Growth Rate Analysis
5.4. Global Catastrophic Antiphospholipid Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Catastrophic Antiphospholipid Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Catastrophic Antiphospholipid Syndrome Total Addressable Market (TAM)
6.1. Global Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anticoagulants
Immunosuppressive Therapy
Plasma Exchange Therapy (Plasmapheresis)
Intravenous Immunoglobulin (IVIG)
Other Treatments
6.2. Global Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
6.3. Global Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Blood Testing
Imaging Techniques
Genetic Testing
6.4. Global Catastrophic Antiphospholipid Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty clinics
Ambulatory surgical centers
Other End-Users
6.5. Global Catastrophic Antiphospholipid Syndrome Market, Sub-Segmentation Of Anticoagulants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Heparin
Low Molecular Weight Heparin (Lmwh)
Warfarin
Direct Oral Anticoagulants (Doacs)
Fondaparinux
6.6. Global Catastrophic Antiphospholipid Syndrome Market, Sub-Segmentation Of Immunosuppressive Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Corticosteroids
Cyclophosphamide
Azathioprine
Mycophenolate Mofetil
Methotrexate
6.7. Global Catastrophic Antiphospholipid Syndrome Market, Sub-Segmentation Of Plasma Exchange Therapy (Plasmapheresis), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Therapeutic Plasma Exchange (Tpe)
Double Filtration Plasmapheresis (Dfpp)
Centrifugal Plasmapheresis
Membrane-Based Plasmapheresis
6.8. Global Catastrophic Antiphospholipid Syndrome Market, Sub-Segmentation Of Intravenous Immunoglobulin (Ivig), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Standard Intravenous Immunoglobulin (Ivig)
High-Dose Intravenous Immunoglobulin (Ivig)
Liquid Intravenous Immunoglobulin (Ivig)
Lyophilized Intravenous Immunoglobulin (Ivig)
6.9. Global Catastrophic Antiphospholipid Syndrome Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Complement Inhibitors
Antiplatelet Agents
Anti-Tumor Necrosis Factor (Tnf) Agents
Organ Support Therapies
7. Catastrophic Antiphospholipid Syndrome Market Regional And Country Analysis
7.1. Global Catastrophic Antiphospholipid Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Catastrophic Antiphospholipid Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Catastrophic Antiphospholipid Syndrome Market
9.1. China Catastrophic Antiphospholipid Syndrome Market Overview
9.2. China Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Catastrophic Antiphospholipid Syndrome Market
10.1. India Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Catastrophic Antiphospholipid Syndrome Market
11.1. Japan Catastrophic Antiphospholipid Syndrome Market Overview
11.2. Japan Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Catastrophic Antiphospholipid Syndrome Market
12.1. Australia Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Catastrophic Antiphospholipid Syndrome Market
13.1. Indonesia Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Catastrophic Antiphospholipid Syndrome Market
14.1. South Korea Catastrophic Antiphospholipid Syndrome Market Overview
14.2. South Korea Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Catastrophic Antiphospholipid Syndrome Market
15.1. Western Europe Catastrophic Antiphospholipid Syndrome Market Overview
15.2. Western Europe Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Catastrophic Antiphospholipid Syndrome Market
16.1. UK Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Catastrophic Antiphospholipid Syndrome Market
18.1. France Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Catastrophic Antiphospholipid Syndrome Market
21.1. Eastern Europe Catastrophic Antiphospholipid Syndrome Market Overview
21.2. Eastern Europe Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Catastrophic Antiphospholipid Syndrome Market
22.1. Russia Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Catastrophic Antiphospholipid Syndrome Market
23.1. North America Catastrophic Antiphospholipid Syndrome Market Overview
23.2. North America Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Catastrophic Antiphospholipid Syndrome Market
24.1. USA Catastrophic Antiphospholipid Syndrome Market Overview
24.2. USA Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Catastrophic Antiphospholipid Syndrome Market
26.1. South America Catastrophic Antiphospholipid Syndrome Market Overview
26.2. South America Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Catastrophic Antiphospholipid Syndrome Market
27.1. Brazil Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Catastrophic Antiphospholipid Syndrome Market
28.1. Middle East Catastrophic Antiphospholipid Syndrome Market Overview
28.2. Middle East Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Catastrophic Antiphospholipid Syndrome Market
29.1. Africa Catastrophic Antiphospholipid Syndrome Market Overview
29.2. Africa Catastrophic Antiphospholipid Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Catastrophic Antiphospholipid Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Catastrophic Antiphospholipid Syndrome Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Catastrophic Antiphospholipid Syndrome Market Competitive Landscape And Company Profiles
